FOXO4-DRI where to buy: start by ruling out the legitimate market
Most buying guides on this site begin by comparing telehealth providers against cash-pay pharmacy prices, because for approved medicines that comparison is the whole decision. For FOXO4-DRI it collapses immediately, and understanding why is more useful than any vendor list.
FOXO4-DRI holds no marketing authorisation from the FDA, the EMA or the MHRA. There is no approved product, which means there is no indication, no label, no prescribing information and nothing for a pharmacist to dispense. A prescriber cannot write for it, because a prescription is an instruction to a pharmacy to supply an approved product, and none exists.
It has also never been given to a human being in a registered clinical trial. Not an early one, not an ongoing one. ClinicalTrials.gov lists no interventional study of this peptide in people. Everything known about it comes from mice, rats and cells in culture.
So the honest answer to where to buy it is: research-peptide suppliers, sold as laboratory material, on laboratory terms. That is not a workaround. It is the only channel that exists.
| Route | Available? | Why |
|---|---|---|
| Pharmacy with a prescription | No | No approved product exists to dispense |
| Telehealth programme | No | A prescriber cannot write for an unapproved compound |
| Compounding pharmacy | No | Not on any bulk substance list for compounding |
| Longevity or med-spa clinic | Not lawfully | Any stock is research-grade or a different compound |
| Research-peptide supplier | Yes | Sold as laboratory material, the only channel that exists |
Why each conventional supply route is unavailable for FOXO4-DRI
What a longevity clinic is actually offering you
This is where readers of this site are most likely to be misled, because the presentation is professional and the setting looks medical.
A clinic advertising a senolytic protocol is using a marketing phrase, not describing a regulatory status. There is no approved senolytic for any indication. If a practice offers FOXO4-DRI specifically, there are only a few possibilities, and none of them is reassuring: they are sourcing the same research-grade material you could buy directly, they are supplying a different compound under a loose label, or they are describing something as senolytic that simply is not.
The tell is what happens when you ask for documentation. A legitimate medical supply chain produces a manufacturer, a lot, and a label. A clinic buying research peptides can produce, at best, the same vendor certificate you could download yourself, and often not even that.
The consumer-protection point is the mark-up. You are paying a clinic premium for a compound with no approval, no established dose, and no human safety data, on top of a supply chain that is no better documented than buying it yourself. The medical setting is doing persuasive work that the evidence does not support.
The criteria that actually separate suppliers
Since the research-supply route is the only route, the real decision is which supplier, and price is close to the least useful signal available.
What matters is whether you can verify what is in the vial. That means a batch-specific certificate naming the lot stamped on your vial, from a laboratory with a real name and address, running purity by HPLC and identity by mass spectrometry rather than purity alone. It means a stated net content figure, which is a different measurement from purity and the one almost nobody publishes. It means domestic dispatch, so customs is not in the path and a return address is real. And it means no human-use claims anywhere on the listing, because a vendor willing to break that boundary is unlikely to be rigorous about batch documentation.
A vial substantially cheaper than the market, sold with no lot number and no named laboratory, is not a bargain. It is an unidentified powder at a discount, and there is no practical way for a buyer to find out otherwise.
What the certificates show, including the part that is awkward
Ascension is the supplier we point readers to, and the reason is that it publishes enough to be checked. It is worth being specific about what that checking reveals, including where the record is mixed.
Two laboratories have certified this product, on two different batches, and they disagree about how much peptide is in the vial. Kovera Labs certified batch 55-05260628 in June 2026 at 99.411% purity with a measured net content of 11.41 mg. MZ Biolabs analysed lot 55-01260229 in January 2026 at 99.97% purity with a measured net content of 8.30 mg. Both vials carried a 10 mg label.
Neither certificate is defective. Purity and quantity are separate measurements, and both purity figures were excellent. But one batch came in roughly 14% above the labelled mass and the other roughly 17% below it, which is a spread no headline price reflects. At $67.00 with the code, that moves the real cost between about $5.87 and $8.07 per milligram.
There is a second difference. The Kovera batch carries an endotoxin screen and a microbial sterility screen. The MZ Biolabs batch carries neither. Testing scope belongs to a batch rather than to a product, so any page telling you this product is endotoxin tested is generalising from one lot. Ask for the certificate matching the lot you receive, because the PDF linked from a product page is not always the batch that ships.
We would rather publish that than a cleaner story. A supplier that discloses measured fill at all is doing more than most of this market, and the honest way to reward that is to report what the disclosure actually says.
| Kovera Labs | MZ Biolabs | |
|---|---|---|
| Batch | 55-05260628 | 55-01260229 |
| Date | Certified 15 June 2026 | Analysed 10 January 2026 |
| Purity | 99.411% | 99.97% |
| Measured net content | 11.41 mg | 8.30 mg |
| Endotoxin screen | Pass | Not performed |
| Sterility screen | No growth | Not performed |
| Effective cost per mg at $67.00 | About $5.87 | About $8.07 |
The two published certificates, side by side
What you are giving up compared with an approved medicine
Readers used to comparing telehealth programmes should see the gap plainly, because it is much wider than the usual cash-pay versus insurance question.
There is no prescriber, so nobody has assessed whether this is appropriate for you or checked it against anything else you take. There is no label, so there is no approved indication and no dosing information with any authority behind it. There is no established human dose at all, because the trials that would establish one have never been run. There is no adverse-event reporting pathway. There is no pharmacy check between manufacturer and buyer.
There is also no guarantee the compound does anything useful in a person. The foundational 2017 work in Cell reported restored fitness, fur density and renal function in aged mice, which is a genuine and striking result in mice. Preclinical results failing to reproduce in humans is the ordinary outcome in drug development, not the exception.
And senolysis is not uniformly beneficial even in principle. Senescent cells suppress tumour formation and assist wound healing, and a 2023 study in Circulation found that clearing them could promote the development and progression of pulmonary hypertension. Anyone presenting this class as risk-free is not describing the literature.
For how we assess peptide suppliers generally, see our NAD source comparison and the epithalon buying guide, and our affiliate disclosure explains how we are paid.